Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ipsen S.A. ADR (OP: IPSEY ) 30.68 -0.49 (-1.57%) Streaming Delayed Price Updated: 3:08 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ipsen S.A. ADR Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing November 10, 2023 Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire International companies to host live webcasts at Deutsche Bank’s Depositary Receipts November 01, 2023 Virtual Investor Conference on November 8th and 9th, 2023 From Virtual Investor Conferences Via GlobeNewswire Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing May 18, 2023 Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 May 09, 2023 From Virtual Investor Conferences Via GlobeNewswire International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 May 15, 2023 From Virtual Investor Conferences Via GlobeNewswire Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. January 27, 2023 From Ipsen Via Business Wire Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI January 20, 2023 From Ipsen Via Business Wire Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases January 09, 2023 From Ipsen Via Business Wire Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva December 23, 2022 From Ipsen Via Business Wire Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy December 08, 2022 From Ipsen Via Business Wire Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma November 09, 2022 From Ipsen Via Business Wire Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance October 27, 2022 From Ipsen Via Business Wire Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting October 25, 2022 From Ipsen Via Business Wire Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology August 12, 2022 From Ipsen Via Business Wire Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 August 05, 2022 From Ipsen Via Business Wire Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer August 03, 2022 From Ipsen Via Business Wire Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic August 01, 2022 From Ipsen Via Business Wire Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance July 28, 2022 From Ipsen Via Business Wire Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission June 29, 2022 From Ipsen Via Business Wire Ipsen to acquire Epizyme, expanding its portfolio in oncology June 27, 2022 From Epizyme, Inc. Via Business Wire Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury June 09, 2022 From Ipsen Via Business Wire Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer May 26, 2022 From Ipsen Via Business Wire Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer May 03, 2022 From Ipsen Via Business Wire Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022 April 27, 2022 From Ipsen Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
